Anthera Pharmaceuticals 

We are focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs.

Find out more about what we are doing for patients with Cystic Fibrosis, Systemic Lupus Erythematosus, and IgA Nephropathy:

Cystic Fibrosis
Systemic Lupus Erythematosus
IgAN

ANTH on NASDAQ

LATEST NEWS

Anthera Pharmaceuticals Appoints Brent Furse to Board of Directors. Read more

Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results. Read more

UPCOMING EVENTS

Anthera to announce 2016 Q1 Operational Update and Financial Results
May 9, 2016

Print Friendly